Emeryville, CA, United States of America

Shreya Pramanick

This inventor holds 1 USPTO granted patent. Top assignee: Crystal Bioscience Inc.. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Shreya Pramanick. Retrieved from https://idiyas.com/inventor/shreya-pramanick

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

% Patents Active = 100.0

Average Co-Inventor Count = 3.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Shreya Pramanick: Innovator in Biopharmaceuticals

Introduction

Shreya Pramanick is a notable inventor based in Emeryville, CA (US). She has made significant contributions to the field of biopharmaceuticals, particularly in the development of innovative therapies.

Latest Patents

Shreya holds a patent for "Human Glucose-Dependent Insulinotropic Polypeptide Receptor (GIPR) Antibodies and Methods of Use Thereof to Inhibit GIP Receptor and Signaling." This patent represents her commitment to advancing medical science and improving treatment options for patients.

Career Highlights

Shreya is currently employed at Crystal Bioscience Inc., where she continues to work on groundbreaking research. Her expertise in biopharmaceuticals has positioned her as a key player in her field.

Collaborations

She collaborates with talented individuals such as William Don Harriman and Shelley Izquierdo, contributing to a dynamic research environment that fosters innovation.

Conclusion

Shreya Pramanick's work exemplifies the spirit of innovation in the biopharmaceutical industry. Her contributions are paving the way for new therapeutic approaches that can significantly impact patient care.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…